Who is sponsoring ENDURANCE-4?

ENDURANCE-4 is sponsored by AbbVie.

What condition does ENDURANCE-4 study?

ENDURANCE-4 studies Hepatitis C Virus.

What drugs are being tested in ENDURANCE-4?

Interventions: ABT-493/ABT-530.

What is the status of ENDURANCE-4?

ENDURANCE-4 is currently COMPLETED.

Last reviewed 2021-07-09 · How we verify

A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

NCT02636595 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) after 12 weeks of treatment with ABT-493/ABT-530 and to evaluate the safety of the regimen in participants with chronic hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.

Details

Lead sponsor	AbbVie
Phase	Phase 3
Status	COMPLETED
Enrolment	121
Start date	2015-11
Completion	2017-01

Conditions

Hepatitis C Virus

Interventions

ABT-493/ABT-530

Primary outcomes

Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 12 weeks after the last actual dose of study drug
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.